102
Participants
Start Date
February 28, 2009
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
Azithromycin
The intravenous formulation 500 mg is administered once daily for 2-5 days; followed by the oral formulation 500 mg will be given once daily to complete a 7 to 10-day course of therapy.
Pfizer Investigational Site, Seto-shi
Pfizer Investigational Site, Touon
Pfizer Investigational Site, Chikushino-shi
Pfizer Investigational Site, Fukuoka
Pfizer Investigational Site, Koga
Pfizer Investigational Site, Yanagawa
Pfizer Investigational Site, Higashihiroshima
Pfizer Investigational Site, Hiroshima
Pfizer Investigational Site, Asahikawa
Pfizer Investigational Site, Himejishi
Pfizer Investigational Site, Moriya
Pfizer Investigational Site, Kanazawa
Pfizer Investigational Site, Takamatsu
Pfizer Investigational Site, Kawasaki
Pfizer Investigational Site, Kochi
Pfizer Investigational Site, Tsu
Pfizer Investigational Site, Sendai
Pfizer Investigational Site, Matsumoto
Pfizer Investigational Site, Emukae, Kitamatsuura
Pfizer Investigational Site, Isahaya
Pfizer Investigational Site, Nagasaki
Pfizer Investigational Site, Sasebo
Pfizer Investigational Site, Niigata
Pfizer Investigational Site, Ōita
Pfizer Investigational Site, Yufu
Pfizer Investigational Site, Kurashiki
Pfizer Investigational Site, Okinawa
Pfizer Investigational Site, Sakai
Pfizer Investigational Site, Ureshinoshi
Pfizer Investigational Site, Hamamatsu
Pfizer Investigational Site, Meguro-Ku
Pfizer Investigational Site, Toshima-ku
Pfizer Investigational Site, Yonezawa
Pfizer Investigational Site, Shiogama
Lead Sponsor
Pfizer
INDUSTRY